About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals is a company based in Watertown (United States) founded in 2006 was acquired by La Jolla Pharmaceutical in June 2020. Tetraphase Pharmaceuticals has raised $80.04 million across 5 funding rounds from investors including La Jolla Pharmaceutical, Flagship Pioneering and Excel Venture Management. The company has 31 employees as of December 31, 2020. Tetraphase Pharmaceuticals operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Watertown, United States
- Employees 31 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$80.04 M (USD)
in 5 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Jan 28, 2020
-
Investors
La Jolla Pharmaceutical
& 7 more
-
Employee Count
31
as on Dec 31, 2020
-
Acquired by
La Jolla Pharmaceutical
(Jun 24, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Tetraphase Pharmaceuticals
Unlock access to complete
Funding Insights of Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals has successfully raised a total of $80.04M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include La Jolla Pharmaceutical, Flagship Pioneering and Excel Venture Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
US life sciences companies are invested in by Skyline Ventures.
|
Locked | Locked | Locked |
Investor details for Tetraphase Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tetraphase Pharmaceuticals
Investment portfolio details for Tetraphase Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tetraphase Pharmaceuticals
Detailed financials for Tetraphase Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tetraphase Pharmaceuticals Comparisons
Peer comparison for Tetraphase Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
Detailed competitors of Tetraphase Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tetraphase Pharmaceuticals
Complete news archive for Tetraphase Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals was founded in 2006.
Tetraphase Pharmaceuticals is headquartered in Watertown, United States.
Tetraphase Pharmaceuticals is a funded company, having raised a total of $80.04M across 5 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Tetraphase Pharmaceuticals is 31.
Tetraphase Pharmaceuticals was founded in 2006 as a clinical-stage biopharmaceutical company based in Watertown, United States. Proprietary chemistry technology is employed to produce novel tetracycline analogs targeting multidrug-resistant infections. A library exceeding 2500 compounds has been assembled and is screened against bacterial targets. The lead candidate, Eravacycline, a fully synthetic fluorocycline antibiotic, is advanced in phase 3 trials for complicated intra-abdominal infections and complicated urinary tract infections.
Tetraphase Pharmaceuticals's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Tetraphase Pharmaceuticals has 8 investors. Key investors include La Jolla Pharmaceutical, Flagship Pioneering, Excel Venture Management, CMEA Capital, and Mediphase Venture Partners.